Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
about
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety profile of currently available diabetic drugs.Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.The Effect of Long-Term Intranasal Serotonin Treatment on Metabolic Parameters and Hormonal Signaling in Rats with High-Fat Diet/Low-Dose Streptozotocin-Induced Type 2 Diabetes.Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitusClinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsBrain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy.Pharmacologic treatment of type 2 diabetes: oral medications.Combination therapy when metformin is not an option for type 2 diabetes.Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.Cardiovascular effects of anti-diabetes drugs.Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.Nonblood/urine biomarker of progression of kidney disease in diabetes mellitus.Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database.Cardiovascular outcome trials of diabetes drugs: lessons learned.Insulin therapy for type 2 diabetes - are we there yet? The d-Nav® story.Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibeCardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events
P2860
Q26740253-6A4ED5B8-8B16-4A1C-B021-ECB527256B2FQ34971736-23FB6D88-3EA7-4465-9A1E-170AF61ED5F6Q35594537-16B859E1-250C-4B06-A692-BB8D00549BFAQ35594627-B1EEB38A-C83C-4E1A-B50F-813F7C63D828Q35739470-F1B3C84D-B173-4A0B-95D6-52B5BDA87859Q36560960-896B9927-152A-4B6D-B956-FBDE7C995E57Q36785475-874F1CE4-A302-470D-AD11-247B74535B13Q37011769-E4FEBBAC-1FAD-465C-9F12-407B6073103FQ37474214-8890149E-3DEC-4C7B-B4C3-ADD283C3567DQ37509313-A2C2869D-42D4-4FAE-8917-E2DBE7E2E03AQ38085727-217FB47B-1E8B-4D88-BE5E-31509041F7E1Q38189113-DCA83201-4BCE-4796-B0F9-59223A0281F5Q38219485-62D25462-6639-454E-8D41-1A12C705A63BQ38350347-3A3FBDE6-3EE3-442C-A6F3-6A4023893FE0Q38377267-BAF41B8E-20D8-4AD0-B1E9-AF988B7F83FFQ38378534-88E39936-9054-40D5-BE24-2E7D36740E99Q38386992-99744A22-F645-40E7-96BB-001C06A34E4FQ38857056-1FEEACDD-E8C8-430F-AF7B-0795C45FBDF2Q38908684-D05CC7A5-93EC-4C22-A516-CA51E68018FAQ38931845-74A6A347-2EB5-4608-B4B9-BF843B291D46Q40305276-9ACD1AEC-8D1C-4CCA-8F20-95B0FEE6D5FDQ42362474-0F7EFB1D-37E3-477E-8767-7A1898208BE6Q44376471-98CAB986-324A-44B9-B04E-94F99AA8A7E2Q50066063-F6E42D6C-31D4-4C38-A128-6895D122B432Q55116866-82B24C5F-39F3-48D5-91EA-919BC5819882Q57150144-998F3938-F382-4E9E-8EF6-E749EC62695BQ58700773-9CF90A43-7D05-4601-9FF5-C64A28EDA4EA
P2860
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@ast
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@en
type
label
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@ast
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@en
prefLabel
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@ast
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@en
P2093
P2860
P356
P1476
Effect of bromocriptine-QR (a ...... s in type 2 diabetes subjects.
@en
P2093
Aaron Vinik
Anthony H Cincotta
J Michael Gaziano
Lawrence Blonde
Nancy Bohannon
Richard Scranton
P2860
P304
P356
10.1161/JAHA.112.002279
P577
2012-10-25T00:00:00Z